• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

理解药代动力学/药效动力学关系中的滞后环难题。

Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

机构信息

University of Manitoba.

出版信息

J Pharm Pharm Sci. 2014;17(1):34-91.

PMID:24735761
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4332569/
Abstract

Hysteresis loops are phenomena that sometimes are encountered in the analysis of pharmacokinetic and pharmacodynamic relationships spanning from pre-clinical to clinical studies. When hysteresis occurs it provides insight into the complexity of drug action and disposition that can be encountered. Hysteresis loops suggest that the relationship between drug concentration and the effect being measured is not a simple direct relationship, but may have an inherent time delay and disequilibrium, which may be the result of metabolites, the consequence of changes in pharmacodynamics or the use of a non-specific assay or may involve an indirect relationship. Counter-clockwise hysteresis has been generally defined as the process in which effect can increase with time for a given drug concentration, while in the case of clockwise hysteresis the measured effect decreases with time for a given drug concentration. Hysteresis loops can occur as a consequence of a number of different pharmacokinetic and pharmacodynamic mechanisms including tolerance, distributional delay, feedback regulation, input and output rate changes, agonistic or antagonistic active metabolites, uptake into active site, slow receptor kinetics, delayed or modified activity, time-dependent protein binding and the use of racemic drugs among other factors. In this review, each of these various causes of hysteresis loops are discussed, with incorporation of relevant examples of drugs demonstrating these relationships for illustrative purposes. Furthermore, the effect that pharmaceutical formulation has on the occurrence and potential change in direction of the hysteresis loop, and the major pharmacokinetic / pharmacodynamic modeling approaches utilized to collapse and model hysteresis are detailed.

摘要

滞后环是在分析从临床前研究到临床研究的药代动力学和药效学关系时有时会遇到的现象。滞后环的出现提供了对药物作用和处置复杂性的深入了解,这种复杂性可能会遇到。滞后环表明,药物浓度与所测量的效应之间的关系不是简单的直接关系,而是可能具有内在的时间延迟和不平衡,这可能是代谢物的结果,药效学变化的结果,或者使用非特异性测定方法的结果,也可能涉及间接关系。逆时针滞后环通常被定义为在给定药物浓度下,效应随时间增加的过程,而在顺时针滞后环的情况下,给定药物浓度下的测量效应随时间减少。滞后环可能是由于许多不同的药代动力学和药效学机制引起的,包括耐受性、分布延迟、反馈调节、输入和输出速率变化、激动剂或拮抗剂活性代谢物、进入活性部位的摄取、受体动力学缓慢、延迟或改变活性、时间依赖性蛋白结合以及使用外消旋药物等因素。在这篇综述中,讨论了这些滞后环的各种原因,并结合了药物的相关实例来说明这些关系。此外,还详细介绍了药物制剂对滞后环发生和潜在方向变化的影响,以及用于压缩和模拟滞后环的主要药代动力学/药效学建模方法。

相似文献

1
Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.理解药代动力学/药效动力学关系中的滞后环难题。
J Pharm Pharm Sci. 2014;17(1):34-91.
2
Pharmacokinetic-pharmacodynamic modeling: time-dependent protein binding--an alternative interpretation of clockwise and counterclockwise hysteresis.药代动力学-药效学建模:时间依赖性蛋白结合——对顺时针和逆时针滞后现象的另一种解释
J Pharm Sci. 1992 Mar;81(3):232-6. doi: 10.1002/jps.2600810309.
3
A semi-compartmental model describing the pharmacokinetic-pharmacodynamic relationship.一个描述药代动力学-药效学关系的半房室模型。
Anesth Pain Med (Seoul). 2020 Jan 31;15(1):1-7. doi: 10.17085/apm.2020.15.1.1.
4
Methodological issues in pharmacokinetic-pharmacodynamic modelling.药代动力学-药效学建模中的方法学问题。
Clin Pharmacokinet. 1998 Aug;35(2):151-66. doi: 10.2165/00003088-199835020-00004.
5
Semiparametric approach to pharmacokinetic-pharmacodynamic data.药代动力学-药效学数据的半参数方法
Am J Physiol. 1989 Apr;256(4 Pt 2):R1005-10. doi: 10.1152/ajpregu.1989.256.4.R1005.
6
Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences.非稳态研究中的药代动力学-药效学(PK-PD)建模及动静脉药物浓度差异
Br J Clin Pharmacol. 1994 Nov;38(5):389-400. doi: 10.1111/j.1365-2125.1994.tb04372.x.
7
Interpretation and utilization of effect and concentration data collected in an in vivo pharmacokinetic and in vitro pharmacodynamic study.体内药代动力学和体外药效学研究中收集的效应和浓度数据的解读与应用。
Pharm Res. 1993 Jun;10(6):889-94. doi: 10.1023/a:1018969429535.
8
Pharmacokinetic and pharmacodynamic modeling in vivo.体内药代动力学和药效学建模
Crit Rev Bioeng. 1981;5(4):273-322.
9
The use of multiple doses and pharmacodynamic system analysis to distinguish between dispositional delays and time-variant pharmacodynamics.使用多剂量和药效学系统分析来区分处置延迟和时变药效学。
Pharm Res. 1994 Dec;11(12):1825-8. doi: 10.1023/a:1018940122382.
10
The use of kinetic-dynamic interactions in the evaluation of drugs.动力学-动态相互作用在药物评估中的应用。
Psychopharmacology (Berl). 1990;100(4):433-50. doi: 10.1007/BF02243994.

引用本文的文献

1
Practical guide to concentration-QTc modeling: a hands-on tutorial.浓度-QTc建模实用指南:实践教程
J Pharmacokinet Pharmacodyn. 2025 Jul 26;52(4):43. doi: 10.1007/s10928-025-09981-8.
2
Quantifying Risk of Delayed QT Prolongation of Ipatasertib in Preclinical and Clinical Studies in Cancer Patients.在癌症患者的临床前和临床研究中量化艾帕替尼延迟QT延长的风险。
Clin Transl Sci. 2025 Jul;18(7):e70298. doi: 10.1111/cts.70298.
3
Pharmacokinetics and Pharmacodynamics of Intranasal Diacetylmorphine in Heroin-Assisted Treatment for Severe Opioid Use Disorder.

本文引用的文献

1
Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods.群体建模、模拟和基于模型的药物研发的基本概念:第 3 部分——药效学建模方法介绍。
CPT Pharmacometrics Syst Pharmacol. 2014 Jan 2;3(1):e88. doi: 10.1038/psp.2013.71.
2
Pharmacokinetic-pharmacodynamic evaluation of the major component astragaloside IV on the immunomodulatory effects of Yu-ping-feng prescription.玉屏风方主要成分黄芪甲苷对免疫调节作用的药代动力学-药效学评价
Eur J Drug Metab Pharmacokinet. 2014 Jun;39(2):103-10. doi: 10.1007/s13318-013-0161-x. Epub 2013 Dec 18.
3
鼻内注射二乙酰吗啡用于重度阿片类物质使用障碍的海洛因辅助治疗的药代动力学和药效学
CNS Drugs. 2025 Aug;39(8):807-817. doi: 10.1007/s40263-025-01189-1. Epub 2025 Jun 7.
4
Time-Dependent Kinetic Complexities in Enzyme Assays: A Review.酶活性测定中的时间依赖性动力学复杂性:综述
Biomolecules. 2025 Apr 30;15(5):641. doi: 10.3390/biom15050641.
5
Pharmacokinetic/Pharmacodynamic Modeling of the Acute Heart Rate Effects of Delta-9 Tetrahydrocannabinol and Its Major Metabolites After Intravenous Injection in Healthy Volunteers.静脉注射Δ⁹ 四氢大麻酚及其主要代谢产物后对健康志愿者急性心率影响的药代动力学/药效学模型
Eur J Drug Metab Pharmacokinet. 2025 May;50(3):229-242. doi: 10.1007/s13318-025-00941-8. Epub 2025 Apr 5.
6
Clinical Effects and Pharmacokinetic Profile of Intramuscular Dexmedetomidine (10 μg/kg) in Cats.猫肌肉注射右美托咪定(10μg/kg)的临床效果和药代动力学特征
Animals (Basel). 2024 Aug 5;14(15):2274. doi: 10.3390/ani14152274.
7
An integrated strategy to evaluate active substances of Astragali Radix-Carthami Flos combination on the treatment of cerebral ischemia reperfusion injury based on TQSM polypharmacokinetics and pharmacodynamics.基于 TQSM 多药代动力学和药效学的黄芪-红花组合治疗脑缺血再灌注损伤活性物质的综合评价策略。
J Food Drug Anal. 2023 Dec 15;31(4):711-738. doi: 10.38212/2224-6614.3477.
8
The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.阿片类物质使用障碍患者伊博加因的药代动力学和药效学。
J Psychopharmacol. 2024 May;38(5):481-488. doi: 10.1177/02698811241237873. Epub 2024 Mar 22.
9
A Review of the Lidocaine in the Perioperative Period.围手术期利多卡因的综述
J Pers Med. 2023 Dec 11;13(12):1699. doi: 10.3390/jpm13121699.
10
Pharmacokinetic-Pharmacodynamic Modeling of Midazolam in Pediatric Surgery.咪达唑仑在小儿外科手术中的药代动力学-药效学建模
Pharmaceutics. 2023 Nov 1;15(11):2565. doi: 10.3390/pharmaceutics15112565.
Pharmacokinetics and pharmacodynamics (PK/PD) of irbesartan in Beagle dogs after oral administration at two dose rates.
口服给予两种剂量率的厄贝沙坦后,其在比格犬体内的药代动力学和药效学(PK/PD)。
Pol J Vet Sci. 2013;16(3):555-61. doi: 10.2478/pjvs-2013-0088.
4
Pharmacokinetics and pharmacodynamics of glycopyrrolate following a continuous-rate infusion in the horse.马连续静脉滴注格隆溴铵后的药代动力学和药效学
J Vet Pharmacol Ther. 2014 Apr;37(2):133-44. doi: 10.1111/jvp.12074. Epub 2013 Jul 31.
5
Pharmacokinetics of glutamate-oxaloacetate transaminase and glutamate-pyruvate transaminase and their blood glutamate-lowering activity in naïve rats.谷氨酸草酰乙酸转氨酶和谷氨酸丙酮酸转氨酶的药代动力学及其在未成熟大鼠中的降低血液谷氨酸活性。
Neurochem Res. 2012 Oct;37(10):2198-205. doi: 10.1007/s11064-012-0843-9. Epub 2012 Jul 31.
6
Lisdexamfetamine and immediate release d-amfetamine - differences in pharmacokinetic/pharmacodynamic relationships revealed by striatal microdialysis in freely-moving rats with simultaneous determination of plasma drug concentrations and locomotor activity.左乙拉西坦和盐酸安非他命 - 通过自由活动大鼠纹状体微透析和同时测定血浆药物浓度和运动活性揭示的药代动力学/药效动力学关系的差异。
Neuropharmacology. 2012 Nov;63(6):1064-74. doi: 10.1016/j.neuropharm.2012.07.008. Epub 2012 Jul 14.
7
Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship.使用 PET 从血浆水平预测脑占有率:在建模关系时,结合药代动力学和药效动力学的优越性。
J Cereb Blood Flow Metab. 2012 Apr;32(4):759-68. doi: 10.1038/jcbfm.2011.180. Epub 2011 Dec 21.
8
Ocular pharmacokinetics of a novel tetrahydroquinoline analog in rabbit: compartmental analysis and PK-PD evaluation.新型四氢喹啉类似物在兔眼中的药代动力学:房室分析和 PK-PD 评价。
J Pharm Sci. 2012 Jan;101(1):414-23. doi: 10.1002/jps.22764. Epub 2011 Sep 20.
9
Enhanced analgesic responses after preferential delivery of morphine and fentanyl to the olfactory epithelium in rats.在大鼠嗅上皮优先递送达马啡和芬太尼后增强的镇痛反应。
Anesth Analg. 2011 Sep;113(3):641-51. doi: 10.1213/ANE.0b013e3182239b8c. Epub 2011 Jun 27.
10
Evaluation of pharmacokinetic and pharmacodynamic relationship for oral sustained-release atenolol pellets in rats.评价大鼠口服缓释阿替洛尔微丸的药代动力学和药效学关系。
J Pharm Biomed Anal. 2011 May 15;55(2):342-8. doi: 10.1016/j.jpba.2011.01.044. Epub 2011 Feb 25.